Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

[Enhancing bladder cancer immunotherapy efficacy in men using bicalutamide / Utilisation de la bicalutamide pour augmenter l'efficacité de l'immunothérapie du cancer de la vessie]

Original in French: Enhancing bladder cancer immunotherapy efficacy in men using bicalutamide / Utilisation de la bicalutamide pour augmenter l'efficacité de l'immunothérapie du cancer de la vessie

Funder: Cancer Research Society

Funding period
CAD 100 K
USD 77 K
Funding amount
Abstract
[Bladder cancer is the 5th most common cancer in North America. It affects men 3-4 times more often than women. It was shown that male sex hormones (androgens) could explain this imbalance between men and women. The most frequent bladder tumors have been treated successfully for nearly 40 years with BCG immunotherapy, a type of therapy that activates the immune system to fight cancer. More recently, a newer form of immunotherapy based on molecules named PD-1 / PD-L1 has shown great success for the treatment of metastatic bladder tumors. However, with all patients responding to these immunotherapies, there is a need to improve treatments. We recently found that enzalutamide, a drug which blocks the action of androgens can improve the efficacy of these immunotherapies in males. This project aims to test the possibility of replacing enzalutamide with bicalutamide, a similar but older drug that is much less expensive, in order to improve the effectiveness of bladder cancer immunotherapy. Bladder cancer is the 5th in incidence in North America . It affects 3 to 4 times more men than women. It has been shown that male sex hormones (androgens) could be responsible for this difference between men and women. The most common tumors (low-grade tumors) have been treated for 40 years with BCG immunotherapy, a type of therapy that aims to activate the immune system to fight cancer. More recently, another form of immunotherapy based on PD-1 / PD-L1 molecules has been hugely successful in the treatment of metastatic bladder cancer. However, not all patients respond to these immunotherapies and improvements are required. We have recently observed that benzalutamide, a drug that blocks the action of androgens, can improve the efficacy of these immunotherapies in males. This project aims to test the possibility of replacing benzalutamide with bicalutamide, a similar but older drug that is much cheaper, to improve the effectiveness of bladder cancer immunotherapy.]
Original in French
Bladder cancer is the 5th most common cancer in North America. It affects men 3-4 times more frequently than women. It was shown that male sex hormones (androgens) could explain this imbalance between men and women. The most frequent bladder tumors (the low stage tumors) have been treated successfully for nearly 40 years with BCG immunotherapy, a type of therapy that activates the immune system to fight cancer. More recently, a newer form of immunotherapy based on molecules named PD-1/PD-L1 has shown great success for the treatment of metastatic bladder tumors. However, with not all patients responding to these immunotherapies, there is a need to improve treatments. We recently found that enzalutamide, a medicament which blocks the action of androgens can improve the efficacy of these immunotherapies in males. This project aims to test the possibility to replace enzalutamide with bicalutamide, a similar but older drug that is much less expensive, in order to improve the efficacy of bladder cancer immunotherapy./Le cancer de la vessie est le 5ième en incidence en Amérique du Nord. Il affecte de 3 à 4 fois plus d�hommes que de femmes. Il a été démontré que les hormones sexuelles mâles (androgènes) pourraient être responsables de cette différence entre les hommes et femmes. Les tumeurs les plus fréquentes (les tumeurs de bas stades) sont traitées depuis 40 ans par immunothérapie BCG, un type de thérapie qui vise à activer le système immunitaire pour lutter contre le cancer. Plus récemment une autre forme d�immunothérapie basée sur les molécules PD-1/PD-L1 a eu un immense succès pour le traitement du cancer de la vessie métastatique. Cependant, ce ne sont pas tous les patients qui répondent à ces immunothérapies et des améliorations sont requises. Nous avons récemment observé que l�enzalutamide, un médicament qui bloque l�action des androgènes, peut améliorer l�efficacité de ces immunothérapies chez les mâles. Ce projet vise à tester la possibilité de remplacer l�enzalutamide par la bicalutamide, un médicament similaire mais plus ancien et qui est beaucoup moins cher, afin d'améliorer l�efficacité de l�immunothérapie du cancer de la vessie.
Similar projects All >
Sorted by: Start Date
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2019 - 2020
Project list item
Identifying Immunological Basis for Bladder Cancer Sex Bias

Canadian Institutes of Health Research to Hyunwoo Kwon, Zihai Li

USD 26,219
2019 - 2022
Project list item
Combatting Bladder Cancer by Inducing Epithelial Turnover

National Cancer Institute to SOMAN N ABRAHAM

USD 203,510
2019 - 2021
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 656,816
2019 - 2024
Project list item
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma

National Cancer Institute to HIKMAT AL-AHMADIE

USD 410,835
2019 - 2024

System

Categories
  • FOR (ANZSRC)

    1107 Immunology

  • RCDC

    Aging

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Immunization

  • RCDC

    Urologic Diseases

  • RCDC

    Vaccine Related

  • HRCS HC

    Cancer

  • HRCS RAC

    5.1 Pharmaceuticals

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science